Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Bone tumors with high mortality and disability have become a major clinical challenge. Herewith, it is necessary to design materials for bone tumor therapy and bone repair. In this work, Fe-doped polypyrrole (Fe-Ppy) and CaO are constructed on sulfonated polyetheretherketone (SP) to form a multistage-responsive coating. The coating achieves long-lasting antitumor through chemodynamic therapy (CDT), photothermal therapy (PTT), and combined immunotherapy. Fe-Ppy acts as an electron pump to replenish Fe through oxidizing -NH- to -N-, which lasts the Fenton reaction and persistently produces reactive oxygen species (ROS) in the tumor microenvironment (TME). CaO selectively provides exogenous HO in response to TME to boost the electron cycle. Stronger near-infrared light absorption due to Fe doping and more photon traps caused by porous structure-induced scattering and refraction diminishment improve the photothermal conversion of modified SP. Furthermore, long-lasting ROS and effective photothermal conversion enhance M1 activation to secrete TNF-α and IFN to kill tumor cells. After tumor therapy, Fe-Ppy@CaO-modified SP could adaptively switch the macrophage to M2 and promote osteogenesis with the abolishment of TME and NIR stimulation. In summary, Fe-Ppy@CaO-modified SP with long-lasting ROS, enhanced photothermal conversion, and immunomodulation is a potential candidate for bone tumor therapy and tissue repair.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acsnano.5c00721 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perovskite Nanozyme-Mediated Sonocatalytic Therapy: A Mitochondrion-Targeted Strategy for Enhanced Cancer Therapy.
ACS Appl Bio Mater
September 2025
School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China.
The generation of reactive oxygen species (ROS) through nanozyme-mediated sonocatalytic therapy has demonstrated remarkable therapeutic efficacy in the field of cancer. Nevertheless, it remains a significant challenge for nanozymes with a single catalytic active center to generate sufficient ROS via Fenton or Fenton-like reactions to effectively induce tumor cell death. In order to enhance the catalytic efficacy, we devised and synthesized a multiple active centre and mitochondrial-targeted perovskite nanozyme (NCFP), doped with cobalt (Co) element, and incorporated 4-carboxybutyltriphenylphosphonium bromide (TPP) as a mitochondrial targeting marker for ultrasound (US)-assisted enzyme-like catalytic treatment of tumors.
View Article and Find Full Text PDFUnderstanding and Addressing Challenges With Electronic Health Record Use in Gynecological Oncology: Cross-Sectional Survey of Multidisciplinary Professionals in the United Kingdom and Co-Design of an Integrated Informatics Platform to Support Clinical Decision-Making.
JMIR Cancer
September 2025
iCARE Secure Data Environment & Digital Collaboration Space, NIHR Imperial Biomedical Research Centre, London, United Kingdom.
Background: Electronic health records (EHRs) are a cornerstone of modern health care delivery, but their current configuration often fragments information across systems, impeding timely and effective clinical decision-making. In gynecological oncology, where care involves complex, multidisciplinary coordination, these limitations can significantly impact the quality and efficiency of patient management. Few studies have examined how EHR systems support clinical decision-making from the perspective of end users.
View Article and Find Full Text PDFComplement Factor I Deficiency With Acute Hemorrhagic Leukoencephalitis and Longitudinally Extensive Transverse Myelitis: A Case Report.
Neurol Neuroimmunol Neuroinflamm
November 2025
Department of Neurology, UC Davis Medical Center, Sacramento, CA.
Objectives: Complement factor I (CFI) deficiency is a rare condition that can present with fulminant relapsing CNS autoinflammation. In this report, we highlight the utility of genetic testing in unexplained CNS autoinflammation.
Methods: This case report describes a young adult with partial CFI deficiency, presenting with acute hemorrhagic leukoencephalitis and longitudinally extensive transverse myelitis.
Identification of Targetable Mutations in Ovarian Cancer.
JCO Precis Oncol
September 2025
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA.
Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.
View Article and Find Full Text PDFGermline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?
JCO Precis Oncol
September 2025
Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
Purpose: Tumor comprehensive genomic profiling (CGP) may detect potential germline pathogenic/likely pathogenic (P/LP) alterations as secondary findings. We analyzed the frequency of potentially germline variants and large rearrangements (LRs) in the RATIONAL study, an Italian multicenter, observational clinical trial that collects next-generation sequencing-based tumor profiling data, and evaluated how these findings were managed by the enrolling centers.
Patients And Methods: Patients prospectively enrolled in the pathway-B of the RATIONAL study and undergoing CGP with the FoundationOne CDx assays were included in the analysis.